ALNY Q2: Revenue Beats $1.17B, TTR Guidance Cut -29%

Alnylam Pharmaceuticals (ALNY) reported second-quarter 2026 earnings on July 30, beating revenue estimates with $1.17 billion in net product revenue, up 74% year over year. AMVUTTRA (patisiran) crossed $1 billion in quarterly revenue for the first time. But the stock plunged 29% after the company cut its full-year TTR franchise guidance.

Alnylam lowered its 2026 TTR net product revenue guidance from $4.4 to $4.7 billion down to $4.2 to $4.5 billion, a $200 million reduction at the midpoint. Total net product revenue guidance fell from $4.9 to $5.3 billion to $4.7 to $5.1 billion. Management attributed the cut to normalization of second-line demand after an initial surge of patients transitioning from tafamidis, the older TTR stabilizer.

The demand shift

The guidance cut reflects a maturation phase in the ATTR-CM launch. Second-line patients, who were already diagnosed and switching from tafamidis, represented easy initial wins but are finite. First-line patients, who are treatment-naive, are the larger and more durable market but require more diagnosis and prescriber education. Management said 80% of new ATTR-CM treatment starts are now first-line, and approximately 80% of U.S. ATTR-CM patients remain untreated, framing the cut as a growth opportunity rather than a ceiling.

The competitive picture improved. Ionis and AstraZeneca’s eplontersen failed in the Phase 3 CARDIO-TTRansform trial on July 9, removing a potential TTR competitor. Generic tafamidis entry was delayed to mid-2031.

Pipeline breadth

Alnylam is expanding beyond TTR. Nucresiran, a next-generation TTR silencer achieving more than 95% knockdown with twice-yearly dosing, is in the Phase 3 TRITON-CM trial enrolling approximately 1,750 patients. Four data readouts are expected in the second half of 2026, including Phase 1 results for ALN-HTT02 in Huntington’s disease and ALN-2232 in obesity. Two new Phase 2 trials were initiated: ALN-6400 in von Willebrand disease and migalastat in Down syndrome-associated Alzheimer’s. Alnylam also announced a BeOne partnership for AMVUTTRA in China and Macau.

The obesity program entering Phase 1 data readout is notable given the frenzy around the GLP-1 market. For more on Alnylam’s RNAi platform in cardiometabolic disease, see our zilebesiran hypertension analysis.

What to watch

The stock reaction reflects investor disappointment at the growth deceleration, but the fundamental demand story has not changed. With roughly 200,000 U.S. ATTR-CM patients and 80% untreated, the market is still underpenetrated. The risk: if first-line adoption stalls, the next guidance cut could be larger. The next near-term readout is the nucresiran Phase 3 TRITON-CM interim, which could validate the next-generation TTR silencer.

What It Means for the Trade

The 29% single-session drop is the market repricing a growth story into a launch-execution story, and the distinction matters for how you trade it. A 29% cut on a $200 million guidance reduction at the midpoint implies the market was pricing years of hypergrowth continuation into the TTR franchise — and the math says the cut itself does not justify that magnitude. This is the classic launch-maturation trade: second-line switchers from tafamidis were a finite, one-time cohort being pulled forward, and the quarter-over-quarter optics were always going to get worse as that pool emptied. The question that actually determines the equity value is first-line penetration velocity, and management’s own framing — 80% of new treatment starts are first-line, 80% of U.S. ATTR-CM patients untreated — says the denominator is intact.

The competitive picture is what turns this from a broken story into a negotiable one. Eplontersen’s CARDIO-TTRansform failure in July removed the nearest direct threat to patisiran’s cardiomyopathy franchise, and generic tafamidis delayed to mid-2031 keeps the standard-of-care price umbrella intact. Those two facts together mean Alnylam retains pricing power and franchise exclusivity through the window where first-line adoption ramps. The guidance cut is a timing problem, not a competitive one. Timing problems in the presence of intact competitive moats are historically buyable; competitive problems are not.

Franchise and Pipeline Context

The deeper story is the pivot from one franchise to a platform. Nucresiran is the critical asset: more than 95% TTR knockdown with twice-yearly dosing would obviate the monthly infusion burden that has constrained patisiran’s addressable population since launch, and the ~1,750-patient TRITON-CM Phase 3 is sized like a trial meant to be definitive. If nucresiran succeeds, Alnylam doesn’t just extend the TTR franchise — it re-launches it at a dosing convenience that infusion-averse cardiologists will actually prescribe, and the 80% untreated population becomes reachable rather than aspirational. That is the single largest swing factor in the model, and the TRITON-CM interim is the next data point on it.

The four second-half readouts — including ALN-HTT02 in Huntington’s and ALN-2232 in obesity — are the optionality layer. The obesity program is the one the market will overreact to in either direction, because any credible RNAi entrant into the cardiometabolic obesity market gets read against the GLP-1 complex. Treat Phase 1 data as mechanism-validation, not commercial forecast: Phase 1 in obesity tells you the target is engaged and the drug is tolerated, nothing about sustained weight loss or the competitive bar. The von Willebrand and Down syndrome-associated Alzheimer’s initiations are earlier still but signal the platform’s breadth beyond TTR — which is the right way to underwrite an RNAi platform company whose flagship franchise just taught investors that even good launches have air pockets.

Risks and What Could Go Wrong

1. The first-line ramp is slower than the 80% untreated framing implies — diagnosis rates, prescriber education, and cardiology referral patterns are the gating items, and another guidance cut in 2027 would force the market to model terminal growth, not a deceleration.
2. TRITON-CM interim data underwhelm: nucresiran is priced as the franchise’s future, and an ambiguous interim readout hits at a far worse moment than this guidance cut did.
3. Tafamidis generics arrive before mid-2031 via challenges or authorized-generic mechanics, collapsing the price umbrella that first-line pricing depends on.
4. The 29% drawdown itself becomes a technical overhang — index and momentum flows exit, and the recovery requires a positive catalyst, not just time.

The position-sizing read: this is now a single-catalyst story into the TRITON-CM interim. The guidance cut gave you a cheaper entry into that binary, but it also told you the market will punish ambiguity in the TTR story without hesitation. Trade the catalyst, don’t marry the guidance.

Source: Alnylam Q2 2026 press release